Pertussis Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

The global pertussis vaccine market is expected to reach an estimated $9.7 billion by 2031 with a CAGR of 5.6% from 2025 to 2031. The major drivers for this market are the growing awareness of the importance of pertussis vaccination, supportive government initiatives to promote pertussis vaccination and continuous development of new pertussis vaccines.

The future of the global pertussis vaccine market looks promising with opportunities in the vaccination center, hospital, and clinic markets.

• Within the type category, Dtap will remain a larger segment due to its significant use as a combination vaccine that protects against diphtheria, tetanus, and pertussis.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to the increasing number of geriatric population and rising pertussis death cases in the region.

Emerging Trends in the Pertussis Vaccine Market

The emerging trends in the pertussis vaccine for prophylaxis market are emerging to meet the demand for vaccination and improvement of health systems. These trends are a result of advancements in technologies, changes in vaccination approaches, and attempts made towards meeting global health needs. It is critical to appreciate these trends to enhance pertussis prevention and troubleshooting pertussis vaccines effectiveness and coverage.

• Enhanced Vaccine Formulations: This advancement includes the formulation of improved comprehensive pertussis vaccines as a key major trend. Former vaccines leave room for improvement and sustained immunity through illness over time. Improvements such as the use of more complex antigens and drug injections that increase response and ease of side effects are considered progression. Enhanced formulations contain better tailoring antigens adjuvant therapy is moving forward the worrying problem of the decreased effect of immunity and better disease prophylaxis.
• Increased Focus on Booster Doses: An increased effort is being made to provide booster doses to sustain immunization towards pertussis, which is believed to be a concern. Revised vaccination schedules have now begun recommending these boosters to adolescents, adults, and pregnant women to ensure their retention. This trend is aimed at tackling the problem of waning immunity and reducing the incidence of pertussis, especially in at risk groups.
• Integration of Combination Vaccines: Pertussis vaccines are being integrated into combination vaccines, which is a growing trend. Immunization schedules and adherence are improved through the use of combination vaccines containing diphtheria and tetanus with pertussis protection. Since this trend makes the practice of vaccination easier, effective disease control is improved.
• Expansion of Global Vaccination Programs: Expansion of global vaccination programs is an important trend that concentrates efforts in areas where there is under coverage low and middle income nations. Alleviating the burden of pertussis on the world population calls for measures to enhance access and affordability of vaccinations. That is significant to realize the aims in preventing the public from the diseases.
• More Emphasis on Surveillance and Data Gathering: More emphasis on surveillance and data gathering is increasingly playing a role in tracking the incidence of pertussis and the uptake of vaccines. Enhanced systems of tracking and data analytics quantify immunization deficits, estimate vaccination effectiveness and optimize public health efforts.

This trend enhances the level of control over the epidemiological processes and helps to make more rational vaccinated population management. Emerging trends in the pertussis vaccine market, in particular new preparations, more attentive administration of boosters, combination vaccines, enhanced Global program expansion, and ENHANCE Surveillance revolutionize vaccination strategies. The aforementioned trends lead to the prevention of the disease and enhance the coverage of the vaccine, in addition to advances in the control of public health.

Recent Developments in the Pertussis Vaccine Market

The recent changes in the pertussis vaccine market provide insight into factors that are making inroads in regards to vaccine effectiveness, availability and public health interventions. Some of the major changes include novel vaccine composition, revised recommendations and expanded vaccination coverage, which increase the effectiveness of preventing and managing pertussis.

• Introduction of New Vaccine Formulations: One of the major milestones is the development and subsequent launching of new pertussis vaccine compositions that have higher efficacy and safety. Such vaccines employ more sophisticated antigens and/ or adjuvants to increase the immune response and the period of protection. The innovations addressed the challenges of waning immunity and the related control of pertussis.
• Updated Vaccination Guidelines: Updated vaccination guidelines now include booster doses for adolescents, adults, and pregnant women. These changes intend to counter the declining levels of immunity and enhance re-assurance to the continuation of protection against the disease. The updated recommendations assist in reducing that morbidity as well as curtailing the extent of overall vaccination deficiency through the respective ages and the vaccines used.
• Filling the Gaps Through the Use of Combination Vaccines: Introducing pertussis into the combination vaccine strategies is improving vaccination services. Vaccine combinations which include pertussis, diphtheria and tetanus needles help in minimizing the number of vaccines that an individual is supposed to take, hence improving the completion rate. This advancement increases the efficiency the vaccination and overall control of the disease.
• Expansion of Immunization Programs: Increasing coverage of immunization programs in particular low- and middle-income populations is a positive step. Programs seeking to enhance vaccine supply and costs address inequities in the public health systems and increase coverage. Expanded programs are most helpful in effectuating control of pertussis at the global level.
• Enhanced Surveillance and Reporting: Improved systems of surveillance and reporting of pertussis are improving the tracking of the disease and monitoring vaccine coverage. Improved data collection plus internal evaluation assists in pinpointing immunization gaps, evaluating vaccine viability, and providing direction on the strategies to tackle public health. This advancement facilitates better control of the disease and more appropriate decisions.

The recent advances in the pertussis vaccine market such as the new formulations available, new guidelines, combined vaccines, new program acquisitions, and out schemas are promoting the containment and reduction of pertussis transmission. These outcomes lead to more efficient vaccination campaigns and improved population health.

Strategic Growth Opportunities for Pertussis Vaccine Market

Strategic growth opportunities for the pertussis vaccine market are developing within multiple applications owing to factors such as technological advancements, increasing healthcare demands, and changes in disease profile. These opportunities are very important in terms of improvement of vaccine uptake and overall population health.

• Expansion in Emerging Markets: There is a considerable opportunity that lies in expanding pertussis vaccination programs in emerging markets regions. A more expensive healthcare system and distribution channels for the vaccine can increase the likelihood of such vaccines accessing the targeted parts of the world. This expansion helps to fill in the gap on the inequalities of health across the whole planet and also helps efforts in eliminating whooping cough from risk regions.
• Development of Next-Generation Vaccines: Looking into the future, there is an opportunity when the next-generation pertussis vaccines with better formulations and delivery systems are created. With regards to better immunological responses, new adjuvants and new kinds of antigens can be used for increased potency and persistence. This innovative process will allow for enhanced disease protection and improved vaccine development.
• Integration with Digital Health Tools: Incorporating pertussis vaccines into electronic health records and vaccination tracking apps is expected to facilitate better vaccine management and administration. Such technologies enhance the scheduling of immunization and offer reminder doses and record immunizations and their reverses making vaccination more efficient.
• Public-Private Partnerships: Public-Private Partnerships (PPPs) have a possibility of being fostered to address issues related to vaccine development, distribution, and access. There are partnerships of governments, global pharmaceutical actors, and issues from Non-profit organizations that spur creativity, enhance the pricing of vaccines tackled, and extend the pool of vaccines available. The partnerships enhance the holistic prevention of vaccination efforts and needy patients seeking aid for better health conditions.
• Enhanced Educational Campaigns: Enhanced educational campaigns designed towards the importance of pertussis vaccination are likely to increase the rates of compliance. Furthermore, public awareness campaigns, which emphasize the need for pertussis vaccination help increase the levels of uptake and therefore better disease prevention.

The future of vaccination practices is likely to be guided by the strategic growth opportunities in the pertussis vaccine market. New markets, the creation of new vaccines, electronic integration and partnerships with a broad variety of stakeholders, improved communication and educational initiatives are likely to change the practice of vaccination greatly. Using these healthier vaccines will increase vaccination rates, and improve health benefits and global health issues.

Pertussis Vaccine Market Drivers and Challenges

There are many drivers and challenges within the pertussis vaccine market such as technology, economy, and regulations. Knowledge of these is critical in the attempts of entry into the market and meeting the public health needs.

The factors responsible for driving the pertussis vaccine market include:

• Technological advancements: Improved formulations and delivery system technology are one major reason for the growth of the pertussis Vaccine Market. These innovations increase the efficacy, safety, and administration of the vaccine which leads to improved prevention of diseases and increased demand for vaccines. It is important to continue investing in these technologies to ensure that no ground is lost in the fight against ongoing and upcoming health issues.
• Increased public awareness: With activities aimed at creating awareness on the dangers of pertussis and the merits of vaccination, the market is experiencing growth. Movement of educating people about pertussis and the vaccination is increasing its demand and intake. This increase in awareness impacts positively on public health efforts.
• Government initiatives and funding: Governments and international agencies are instrumental in developing pertussis vaccination programs. The introduction of pertussis vaccines within the established national immunization programs and/ or raising additional funds for the mobilization of people for vaccination programs helps to increase coverage and availability. This subsequent result helps in the timely appropriateness of vaccination and reducing the incidence of pertussis.
• Research and Development: There exists no favorite contribution and one can just enumerate the reproductive health D and D programs and interventions. The development of new pertussis vaccines continues, due to scientific research combined with the measures envisaged in the sphere of healthcare. It is this steady flow of innovation that enables better results in public health and offers improved vaccination strategies.
• Global Health Programs: In the markets of vaccines against pertussis aimed at increasing the vaccination coverage of disadvantaged low-income and middle-income countries, there are considerable growth prospects. Strategies for improving the availability and cost of vaccines bear positive results in decreasing global cases of pertussis. Such programs enhance recognition of and reduce inequalities in health globally.

Challenges in the pertussis vaccine market are:

• High Production Costs: The high costs of producing pertussis vaccines, on the other hand, can be a hindrance in developing the market. Research and analysis, utilization of technology as well as engineering are likely to be costly which makes them hard to be banked for easier transportation and use. The very burden of these costs impairs availability and vaccination in most cases especially in poorer countries.
• Regulatory Hurdles: Pertussis vaccine development is not governed freely within any such market therapeutic areas and one of such challenges is the Regulatory climate. Regulatory constraint comes in terms of a huge amount of instructions and a lot of additional waiting time for finalization of a vaccine. Even though the market investigates acceptable conditions and considers bringing about the change, such preparation consumes a vast amount of money.
• Problems faced in Supply Chain: Problems in the supply chain can have an adverse effect on vaccine provision and access. Potential difficulties in a pertussis vaccine supply chain could be logistics, delays in transportation, or limitations in production capacities especially in rural or less developed regions. Overcoming these challenges is important so that vaccination can be performed whenever it is expected to be.

Several factors shape the pertussis vaccine market, such as technology, awareness, government’s efforts, research funding, and health programs. The vaccine markets also have some existing barriers to market growth and access such as high production costs, regulation challenges, and the supply chain. Integration of these aspects is significant in maximizing vaccine utilization and improving health status of populations.

List of Pertussis Vaccine Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies pertussis vaccine companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the pertussis vaccine companies profiled in this report include:

• Protein Sciences
• GlaxoSmithKline
• Sanofi Pasteur
• Seqirus
• Merck Sharp & Dohme
• Novartis
• Astellas Pharma

Pertussis Vaccine by Segment

The study includes a forecast for the global pertussis vaccine market by type, end use, and region.

Type [Analysis by Value from 2019 to 2031]:

• Dtap Vaccine
• Tdap Vaccine

End Use [Analysis by Value from 2019 to 2031]:

• Vaccination Centers
• Hospitals
• Clinics
• Others

Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country-Wise Outlook for the Pertussis Vaccine Market

The recent trends in the pertussis vaccine market portray how they are still working on the prevention of children even further, extending vaccination, and also looking for new epidemiological risks. Such upcoming markets like the United States, China, and Germany to some extent, India and Japan in particular have included vaccine efficacy and prevention enhancements such as vaccine formulation improvement, a schedule change of immunizations, and health improvement activities. These advances are crucial for the control of whooping cough and for the control of vaccination strategies around the world.

• United States: In the United States, in the pertussis vaccine market, recent developments include the incorporation of newer versions of the vaccine and revised changes in the existing vaccine schedules. The CDC has expanded its recommendations to include the Tdap booster in adolescents and adults to address waning immunity. There has been an improvement in the tracking of pertussis cases and vaccine coverage due to better surveillance and reporting systems. Campaigns aimed at improving knowledge and vaccination levels to reduce newborn pertussis infections by raising vaccination rates among pregnant women.
• China: In China, the place has fortified its pertussis vaccine market by execution changes in its national immunization programs and targeting newer vaccine formulations. New vaccines were provided with higher effectiveness and durability. Also, actions are on the way to increase vaccination levels in rural regions and among the vulnerable. Furthermore, the country plans more funds for the study of vaccines targeting new strains and improving strategies against the disease.
• Germany: Germany has incorporated more age groups in the focal groups of pertussis vaccination by advancing its policies on routine childhood immunization for net protection against diseases. In new advances, it has created new combination vaccines incorporating vaccination against tuberculosis, whooping cough and diphtheria. In the fight against pertussis, the major focus of German healthcare policies is on providing booster vaccinations and making shots more available.
• India: In India, some of the changes in the pertussis vaccine market are the introduction of cheap vaccines, and the vaccines being extended to more children. The vaccination program was integrated into the government system and new vaccines for pertussis became part of the policy with the elucidation of basic coverage in remote regions. Health campaigns are geared towards educating the public and making vaccines better available which as a result ensures that pertussis is contained more effectively.
• Japan: Japan's vaccine against whooping cough has also progressed with regards to enhancing its vaccination program and including fresh puddle forms of pertussis vaccines. Recently, these efforts have included improving vaccine distribution systems and launching public health campaigns to enhance vaccine uptake. Japan even has plans to research to develop effective vaccines and tackle pertussis outbreaks while still being able to keep the levels of cared vaccination high.

Features of this Global Pertussis Vaccine Market Report

• Market Size Estimates: Pertussis vaccine market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Pertussis vaccine market size by type, end use, and region in terms of value ($B).
• Regional Analysis: Pertussis vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the pertussis vaccine market.
• Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the pertussis vaccine market.
• Analysis of competitive intensity of the industry based on Porter’s Five Forces model. expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M&A, and more.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the pertussis vaccine market by type (Dtap vaccine and Tdap vaccine), end use (vaccination centers, hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?